<abstract xmlns="http://www.w3.org/1999/xhtml">

Iron is a crucial mineral for our organism and its deficiency can cause serious health problems such as anaemia, fatigue, and impaired physical fitness. It has been shown that anaemia or iron deficiency is very common in patients with cancer. These patients benefit from iron supplementation either in intravenous or oral form. Our patient is a 67-year-old Russian woman with pancreatic cancer diagnosed in 2019. She fought off lymphocytic leukaemia in 2015. She refused treatment for her pancreatic cancer. The specific type of pancreatic cancer was not specified as the patient chose not to undergo targeted testing. Between March 2020 and February 2023, she took the dietary supplement Synthesit for three cycles (1 cycle lasted about a month).
After taking the dietary supplement, a total percentage of neutrophils became in the reference range. Subjectively, the patient started to feel better after taking Synthesit and her quality of life and well-being has improved as well. It might be supposed that the dietary supplement could have some effect on her well-being and various blood parameters such as white cells count.
Even though the dietary supplement is not supposed to be used for treatment of diseases, it can change some blood parameters and improve the immune system.
This short case study presents the patient with pancreatic cancer who started to take the dietary supplement Synthesit which contains iron in the form of citrate salt in a dosage of 800 μg per capsule, 1 capsule per day. The dietary supplement was administered over three treatment cycles (1 cycle took about a month) from March 2020 to February 2023. It describes a difference in blood test results before taking Synthesit and after the administration of Synthesit.
</abstract>

Iron is a crucial mineral for our organism and its deficiency can cause serious health problems such as anaemia, fatigue, and impaired physical fitness. It has been shown that anaemia or iron deficiency is very common in patients with cancer. These patients benefit from iron supplementation either in intravenous or oral form. Our patient is a 67-year-old Russian woman with pancreatic cancer diagnosed in 2019. She fought off lymphocytic leukaemia in 2015. She refused treatment for her pancreatic cancer. The specific type of pancreatic cancer was not specified as the patient chose not to undergo targeted testing. Between March 2020 and February 2023, she took the dietary supplement Synthesit for three cycles (1 cycle lasted about a month).
After taking the dietary supplement, a total percentage of neutrophils became in the reference range. Subjectively, the patient started to feel better after taking Synthesit and her quality of life and well-being has improved as well. It might be supposed that the dietary supplement could have some effect on her well-being and various blood parameters such as white cells count.
Even though the dietary supplement is not supposed to be used for treatment of diseases, it can change some blood parameters and improve the immune system.
This short case study presents the patient with pancreatic cancer who started to take the dietary supplement Synthesit which contains iron in the form of citrate salt in a dosage of 800 μg per capsule, 1 capsule per day. The dietary supplement was administered over three treatment cycles (1 cycle took about a month) from March 2020 to February 2023. It describes a difference in blood test results before taking Synthesit and after the administration of Synthesit.

Iron Citrate (Synthesit) Supplementation During Pancreas Cancer Showed Surprising Results – Case Study

Acta Medica Martiniana

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Iron is a crucial mineral for our organism and its deficiency can cause serious health problems such as anaemia, fatigue, and impaired physical fitness. It has...

December 2019				March 2023
Fraction	%	Reference range %	g/l	g/l	Reference range
Albumin	62.9	60.3 – 72.8	44.0	41.4	37.5 – 50.1
Alpha1-globulins	2.2	1.0 – 2.6	1.5	3.0	1.9 – 4.6
Alpha2-globulins	8.6	7.2 – 11.8	6.0	6.1	4.8 – 10.5
Beta1-globulins	6.0	5.6 – 9.1	4.2	-	-
Beta2-globulins	3.3	2.2 – 5.7	2.3	-	-
Beta-globulins	-	-	-	6.8	4.8 – 11.0
Gamma-globulins	17.0>	6.2 – 15.4	11.9	11.7	6.2 – 15.1
Albumin/Globulin ratio	1.70	1.2 – 2.0	-	1.5	1.2 – 2.0
Monoclonal IgG kappa	0.9	-	0.6	-	-
Total protein	69.9	62 – 81	-	67	62 – 81

Parameter	Before taking Synthesit 02/2020	During taking Synthesit 7/2021	After taking Synthesit 03/2023	Reference range	Unit of measurement
Haematocrit	40.9	-	42.7	35.0 – 47.0	%
Haemoglobin	14.0	14.8	14.5	11.7 – 16.0	g/dl
Erythrocytes	4.58	4.90	4.72	3.80 – 5.30	*10⁶/μl
Thrombocytes	116	260	123	150 – 400	*10³/μl
Leukocytes	7.07	4.20	6.80	4.50 – 11	*10³/μl
Neutrophils (total), %	40.30	66	48.40	48.0 – 78.0	%
Lymphocytes, %	50.5	-	44.1	19.0 – 37.0	%
Monocytes, %	7.5	-	5.6	3.0 – 11.0	%
Eosinophils, %	1.4	3	1.6	1.0 – 5.0	%
Basophils, %	0.3	-	0.3	<1.0	%
Neutrophils abs.	2.85	-	3.29	1.56 – 6.13	*10³/μl
Lymphocytes abs.	3.57	-	3.00	1.18 – 3.74	*10³/μl
Monocytes abs.	0.53	1	0.38	0.20 – 0.95	*10³/μl
Eosinophils abs.	0.10	-	0.11	0.00 – 0.70	*10³/μl
Basophils abs.	0.02	-	0.02	0.00 – 0.20	*10³/μl
Erythrocyte Sedimentation Rate (ESR)	12	4	7	<30	mm/h

Iron Citrate (Synthesit) Supplementation During Pancreas Cancer Showed Surprising Results – Case Study

Published Online: Dec 31, 2023

Page range: 107 - 116

Received: Aug 09, 2023

Accepted: Nov 11, 2023

DOI: https://doi.org/10.2478/acm-2023-0014

Keywords
pancreatic cancer, iron supplementation, iron citrate

© 2023 Patrik Kusnir, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Fig. 1

Analyses of blood plasma proteins done in December 2019 and March 2023. Parameters that were out of the reference range are highlighted. Values marked as dash mean no data available.

Blood analyses before taking Synthesit in February 2020, during taking in July 2021, and after taking it in March 2023. Parameters that were out of the reference range are highlighted. Values marked as dash mean no data available.

Iron Citrate (Synthesit) Supplementation During Pancreas Cancer Showed Surprising Results – Case Study

Published Online: Dec 31, 2023

Page range: 107 - 116

Received: Aug 09, 2023

Accepted: Nov 11, 2023

DOI: https://doi.org/10.2478/acm-2023-0014

Keywordspancreatic cancer, iron supplementation, iron citrate

© 2023 Patrik Kusnir, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Fig. 1

Analyses of blood plasma proteins done in December 2019 and March 2023. Parameters that were out of the reference range are highlighted. Values marked as dash mean no data available.

Blood analyses before taking Synthesit in February 2020, during taking in July 2021, and after taking it in March 2023. Parameters that were out of the reference range are highlighted. Values marked as dash mean no data available.

Keywords
pancreatic cancer, iron supplementation, iron citrate